<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Erysipelothrix infection
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Erysipelothrix infection
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Erysipelothrix infection
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Annette C Reboli, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Daniel J Sexton, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Sandra Nelson, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Keri K Hall, MD, MS
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Aug 16, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         <em>
          Erysipelothrix rhusiopathiae
         </em>
         is a pleomorphic, non-spore forming, gram-positive bacillus capable of causing self-limited soft tissue infection or serious systemic infection.
         <em>
          E. rhusiopathiae
         </em>
         is widespread in nature around the world and also infects domestic and marine animals; it is found in sheep, horses, cattle, chickens, turkeys, crabs, fish, dogs, and cats [
         <a href="#rid1">
          1
         </a>
         ]. The risk may be highest from swine exposure because of the large number of exposed farmers.
        </p>
        <p>
         Infection in humans is usually due to occupational exposure. Thus, slaughterhouse workers, butchers, fishermen, aquarium workers, farmers, and veterinarians are at risk for infection with
         <em>
          E. rhusiopathiae
         </em>
         [
         <a href="#rid2">
          2-5
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          PATHOGENESIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Little is known about the pathogenesis of human
         <em>
          E. rhusiopathiae
         </em>
         infection. The following observations have been made in vitro and in animal studies:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <em>
          E. rhusiopathiae
         </em>
         is a virulent organism with a capsule that resists phagocytosis and may contribute to intracellular survival (in the absence of opsonization with specific antibody) [
         <a href="#rid6">
          6,7
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Intracellular survival of virulent organisms in macrophages is associated with reduced stimulation of the oxidative respiratory burst [
         <a href="#rid7">
          7
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The SpaA protein is a surface antigen of
         <em>
          E. rhusiopathiae
         </em>
         . It acts as an adhesion protein for the attachment of
         <em>
          E. rhusiopathiae
         </em>
         to host cells [
         <a href="#rid8">
          8
         </a>
         ]. The pathogenic significance of this protein was suggested in a mouse model in which exposure to SpaA antigen was protective in a vaccination system [
         <a href="#rid9">
          9
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The enzymes neuraminidase and hyaluronidase may contribute to the pathogenicity of
         <em>
          Erysipelothrix
         </em>
         [
         <a href="#rid10">
          10
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Other virulence factors include cell wall–associated proteins such as transporter and adhesion proteins [
         <a href="#rid11">
          11
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h1">
          CLINICAL MANIFESTATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The clinical spectrum of human infection includes three major forms of disease:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Localized cutaneous (erysipeloid) infection
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Diffuse cutaneous infection
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Systemic infection (bacteremia with or without endocarditis)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h2">
          Localized cutaneous infection
         </span>
         <span class="headingEndMark">
          —
         </span>
         The most common form of human infection due to
         <em>
          E. rhusiopathiae
         </em>
         is the localized cutaneous form, known as erysipeloid of Rosenbach [
         <a href="#rid12">
          12
         </a>
         ]. When localized infection occurs, it is a usually subacute cellulitis and involves the fingers and/or hands (the sites of exposure). Abrasions or wounds of the skin serve as the portal of entry of the organism. As an example, erysipeloid has been described on the fingers or hands of fisherman or seafood packers who suffer minor trauma while handling contaminated shrimp, crab, or fish [
         <a href="#rid13">
          13,14
         </a>
         ]. Infection can also occur following cat or dog bites. In a review from 18 emergency departments in the United States,
         <em>
          E. rhusiopathiae
         </em>
         was isolated from 2 of 57 patients with infected cat bites [
         <a href="#rid15">
          15
         </a>
         ].
        </p>
        <p>
         The incubation period following inoculation may last two to seven days. Symptoms begin with pain at the site of inoculation (described as throbbing, itching, burning, or tingling). The skin lesion typically progresses slowly from a small red macule at the inoculation site to a well-developed violaceous lesion with central clearing and a raised border. Swelling is typically minimal; patients typically complain of stiffness and pain in the involved fingers. Local lymphangitis and adenitis occur in approximately 30 percent of cases. Systemic symptoms such as high fever or chills are uncommon (about 10 percent of patients) [
         <a href="#rid16">
          16
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h2">
          Diffuse cutaneous infection
         </span>
         <span class="headingEndMark">
          —
         </span>
         Diffuse cutaneous disease is characterized by proximal progression of involvement from the inoculation site and/or involvement of additional sites; such cases are rare [
         <a href="#rid12">
          12
         </a>
         ]. Lesions may be urticarial or bullous, and these patients frequently have fever and arthralgia. Blood cultures are usually negative [
         <a href="#rid12">
          12
         </a>
         ].
        </p>
        <p>
         Most patients with diffuse cutaneous infection have the same types of exposures as those with localized cutaneous infection. However, eating contaminated seafood or undercooked pork has been associated with diffuse cutaneous disease. In such cases, it is presumed that bacteremia precedes the appearance of diffuse cutaneous disease.
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h2">
          Systemic infection
         </span>
         <span class="headingEndMark">
          —
         </span>
         Systemic infection with bacteremia is relatively uncommon. Most patients present with fever. Approximately 40 percent of patients with systemic infection have antecedent or concurrent skin lesions suggestive of erysipeloid [
         <a href="#rid3">
          3
         </a>
         ]. Cutaneous serpiginous lesions or multiple bullous lesions on the trunk and extremities may be seen. Patients with severe underlying liver or heart disease and systemic infection due to
         <em>
          Erysipelothrix
         </em>
         infection may have a clinical presentation resembling gram-negative sepsis [
         <a href="#rid17">
          17
         </a>
         ].
        </p>
        <p>
         The epidemiologic exposures in patients with systemic infection are the same as those for localized cutaneous infection; persistent bacteremia has been reported after the ingestion of contaminated meat. Chronic liver disease is an important predisposing factor; more than one-third of patients with systemic infection are people with an alcohol use disorder [
         <a href="#rid3">
          3,12,18
         </a>
         ]. Bacteremia may also be seen in other immunocompromised patients, especially those receiving corticosteroid and/or cytotoxic drug therapy [
         <a href="#rid17">
          17,19,20
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h3">
          Endocarditis
         </span>
         <span class="headingEndMark">
          —
         </span>
         <em>
          E. rhusiopathiae
         </em>
         bacteremia is often complicated by endocarditis; in one report, 90 percent of 49 cases of serious infection had proven or presumed endocarditis [
         <a href="#rid3">
          3
         </a>
         ]. However, this figure may be a falsely elevated rate due to reporting bias in case reports, since a number of cases with bacteremia in the absence of endocarditis have also been reported [
         <a href="#rid17">
          17,19-23
         </a>
         ].
        </p>
        <p>
         Nearly all reported cases of endocarditis have involved native heart valves, with propensity for involvement of the aortic valve [
         <a href="#rid3">
          3,24-30
         </a>
         ].
         <em>
          Erysipelothrix
         </em>
         endocarditis frequently causes extensive valve destruction. In one series, one-third of patients died and an additional one-third required valve replacement [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p>
         Complications of
         <em>
          Erysipelothrix
         </em>
         endocarditis may include congestive heart failure, valve perforation, myocardial abscess, cerebral infarctions, and acute renal failure due to proliferative glomerulonephritis [
         <a href="#rid31">
          31
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h3">
          Other manifestations
         </span>
         <span class="headingEndMark">
          —
         </span>
         Uncommon forms of infection due to
         <em>
          E. rhusiopathiae
         </em>
         include brain abscess, meningitis, endophthalmitis, intra-abdominal abscess, psoas abscess, osteomyelitis (including vertebral osteomyelitis), spondylodiscitis, septic arthritis, prosthetic joint infection, tenosynovitis, epidural and paravertebral abscesses, pneumonia, necrotizing fasciitis, and peritoneal dialysis-related peritonitis with bacteremia [
         <a href="#rid19">
          19,32-47
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h1">
          DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         A provisional diagnosis can often be made based on a history of appropriate epidemiologic exposure together with the characteristic physical findings.
         <em>
          Erysipelothrix
         </em>
         infection might be suspected in cutaneous or systemic gram-positive infections that fail to respond to
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         . Gram stain and culture of aspirated material are often negative because the organism is deep within the dermis.
        </p>
        <p>
         Organisms may be isolated from the blood with routine commercial blood culture media; growth is usually recognized in two to three days. However, errors in identification can occur; the organism has been misidentified as
         <em>
          Lactobacillus
         </em>
         or
         <em>
          Enterococcus
         </em>
         species [
         <a href="#rid48">
          48
         </a>
         ]. Commercial systems such as Vitek2 and the API system identify
         <em>
          E. rhusiopathiae
         </em>
         reliably.
         <em>
          E. rhusiopathiae
         </em>
         has been identified by 16SrRNA-based gene sequencing from culture-negative, surgically excised heart valves [
         <a href="#rid49">
          49
         </a>
         ]. Matrix-assisted laser desorption/ionization–time of flight mass spectroscopy (MALDI-TOF MS) accurately and rapidly identifies
         <em>
          Erysipelothrix
         </em>
         [
         <a href="#rid30">
          30,50
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1057147395">
         <span class="h1">
          DIFFERENTIAL DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The differential diagnosis of localized cutaneous infection (erysipeloid) includes streptococcal or staphylococcal cellulitis. The diagnosis of erysipeloid is favored by a history of occupational exposure, lesions on the fingers, a subacute course, violaceous hue (as opposed to erythema), absence of suppuration, absence of pitting edema, and pain out of proportion with physical findings.
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h1">
          TREATMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         Erysipeloid skin lesions may resolve in the absence of specific therapy; spontaneous resolution typically occurs within three weeks [
         <a href="#rid51">
          51
         </a>
         ]. However, appropriate antibiotic therapy shortens the clinical illness and reduces the risk of relapse [
         <a href="#rid24">
          24
         </a>
         ]. Local heat may be helpful for patients with arthritis and painful, swollen lesions. Surgical incision or debridement of localized lesions is not indicated.
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h2">
          Antibiotic susceptibility
         </span>
         <span class="headingEndMark">
          —
         </span>
         Penicillin is the drug of choice for all forms of
         <em>
          Erysipelothrix
         </em>
         infection based on in vitro data; there are no comparative clinical trials (
         <a class="graphic graphic_table graphicRef73058" href="/z/d/graphic/73058.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid2">
          2-5,17,18,20,21,24,51-53
         </a>
         ].
         <a class="drug drug_general" data-topicid="8673" href="/z/d/drug information/8673.html" rel="external">
          Amoxicillin
         </a>
         may be used as first-line therapy for localized skin infection [
         <a href="#rid54">
          54
         </a>
         ]. In vitro, penicillin and
         <a class="drug drug_general" data-topicid="8553" href="/z/d/drug information/8553.html" rel="external">
          imipenem
         </a>
         are the most active agents; other active agents include other beta-lactam antibiotics such as cephalosporins, fluoroquinolones,
         <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">
          clindamycin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">
          daptomycin
         </a>
         , and
         <a class="drug drug_general" data-topicid="10283" href="/z/d/drug information/10283.html" rel="external">
          linezolid
         </a>
         [
         <a href="#rid55">
          55,56
         </a>
         ]. Penicillin resistance has been described [
         <a href="#rid57">
          57
         </a>
         ].
        </p>
        <p>
         Agents that are not consistently active against
         <em>
          Erysipelothrix
         </em>
         include macrolides, tetracyclines, and
         <a class="drug drug_general" data-topicid="9241" href="/z/d/drug information/9241.html" rel="external">
          chloramphenicol
         </a>
         ; these should not be used in the treatment of disseminated infection.
         <em>
          E. rhusiopathiae
         </em>
         is typically resistant to sulfonamides,
         <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">
          trimethoprim-sulfamethoxazole
         </a>
         ,
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         , and aminoglycosides [
         <a href="#rid3">
          3,52,53
         </a>
         ]. Intrinsic resistance to vancomycin is a clinically relevant characteristic, since this antibiotic is often used empirically in treatment of gram-positive infections. However, limited data suggest that
         <em>
          Erysipelothrix
         </em>
         is susceptible to
         <a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">
          daptomycin
         </a>
         [
         <a href="#rid55">
          55
         </a>
         ]. Bacteremia caused by penicillin-resistant
         <em>
          Erysipelothrix
         </em>
         has been described; the patient was successfully treated with
         <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">
          ceftriaxone
         </a>
         [
         <a href="#rid57">
          57
         </a>
         ]. Resistance to
         <a class="drug drug_general" data-topicid="9214" href="/z/d/drug information/9214.html" rel="external">
          cefazolin
         </a>
         has been described [
         <a href="#rid58">
          58
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h2">
          Clinical approach
         </span>
         <span class="headingEndMark">
          —
         </span>
         The approach to antibiotic therapy depends on the clinical manifestations and results of blood cultures (
         <a class="graphic graphic_table graphicRef73058" href="/z/d/graphic/73058.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p>
         For localized cutaneous infection, oral therapy with
         <a class="drug drug_general" data-topicid="9751" href="/z/d/drug information/9751.html" rel="external">
          penicillin V
         </a>
         (500 mg every 6 hours) or
         <a class="drug drug_general" data-topicid="8673" href="/z/d/drug information/8673.html" rel="external">
          amoxicillin
         </a>
         (500 mg every 8 hours) should be administered;
         <a class="drug drug_general" data-topicid="9231" href="/z/d/drug information/9231.html" rel="external">
          cephalexin
         </a>
         (500 mg every 6 hours) is an acceptable regimen in the absence of immediate hypersensitivity to penicillin. In the setting of penicillin allergy,
         <a class="drug drug_general" data-topicid="9267" href="/z/d/drug information/9267.html" rel="external">
          ciprofloxacin
         </a>
         (250 mg every 12 hours) or
         <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">
          clindamycin
         </a>
         (300 mg every 8 hours) may be administered. Seven days of therapy is usually curative based on case reports and case series; the 2014 Infectious Diseases Society of America (IDSA) guidelines recommend 7 to 10 days of treatment for erysipeloid [
         <a href="#rid54">
          54
         </a>
         ]. Five days of therapy may also be sufficient based on current therapy for other forms of cellulitis if there is a clinical response.
        </p>
        <p>
         For diffuse cutaneous disease or systemic infection, parenteral therapy should be administered with
         <a class="drug drug_general" data-topicid="9749" href="/z/d/drug information/9749.html" rel="external">
          penicillin G
         </a>
         (2 to 4 million units every 4 hours). Alternative therapies include
         <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">
          ceftriaxone
         </a>
         (2 g once daily),
         <a class="drug drug_general" data-topicid="8553" href="/z/d/drug information/8553.html" rel="external">
          imipenem
         </a>
         (500 mg every 6 hours), or a fluoroquinolone (
         <a class="drug drug_general" data-topicid="9267" href="/z/d/drug information/9267.html" rel="external">
          ciprofloxacin
         </a>
         400 mg every 12 hours or
         <a class="drug drug_general" data-topicid="9554" href="/z/d/drug information/9554.html" rel="external">
          levofloxacin
         </a>
         500 mg once daily) or
         <a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">
          daptomycin
         </a>
         (6 mg/kg intravenously once daily) [
         <a href="#rid55">
          55
         </a>
         ]. The treatment duration should be guided by the clinical response and the underlying health of the patient. Many patients with diffuse cutaneous disease can be switched to oral therapy after clinical response occurs. Short courses of antibiotic therapy (eg, 5 to 10 days) are often curative in such patients; the 2014 IDSA guidelines recommend 7 to 10 days of treatment [
         <a href="#rid54">
          54
         </a>
         ]. For patients with bacteremia in the absence of endocarditis or signs of metastatic infection, some experts favor a minimum of four weeks of therapy [
         <a href="#rid3">
          3,24
         </a>
         ]. Two weeks of intravenous therapy followed by two to four weeks of oral therapy has also been successful [
         <a href="#rid24">
          24
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <em>
          Erysipelothrix rhusiopathiae
         </em>
         is a gram-positive bacillus capable of causing self-limited soft tissue infection or serious systemic infection in humans. It is widespread in nature and infects domestic animals. Infection in humans is usually due to occupational exposure. Slaughterhouse workers, butchers, fishermen, farmers, and veterinarians are at risk for infection with
         <em>
          E. rhusiopathiae
         </em>
         . (See
         <a class="local">
          'Introduction'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         There are three major forms of disease: localized cutaneous (erysipeloid) infection, diffuse cutaneous infection, and systemic infection (bacteremia with or without endocarditis). (See
         <a class="local">
          'Clinical manifestations'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Localized cutaneous infection is a subacute cellulitis that usually involves the fingers and/or hands; abrasions or wounds of the skin serve as the portal of entry of the organism. Following an incubation period of two to seven days, symptoms begin with pain at the site of inoculation. The skin lesion typically progresses from a small red macule at the inoculation site to a well-developed violaceous lesion with central clearing and a raised border. (See
         <a class="local">
          'Localized cutaneous infection'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Diffuse cutaneous disease is characterized by proximal progression of involvement from the inoculation site and/or involvement of additional sites. Lesions may be urticarial or bullous, and these patients frequently have fever and arthralgia. (See
         <a class="local">
          'Diffuse cutaneous infection'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Systemic infection with bacteremia (with or without endocarditis) presents with fever; approximately 40 percent of patients with systemic infection also have antecedent or concurrent skin lesions suggestive of erysipeloid.
         <em>
          E. rhusiopathiae
         </em>
         bacteremia is often complicated by endocarditis. (See
         <a class="local">
          'Systemic infection'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A provisional diagnosis can be made based on a history of appropriate epidemiologic exposure together with the characteristic physical findings. Organisms may be isolated from the blood with routine commercial blood culture media; growth is usually recognized in two to three days. (See
         <a class="local">
          'Diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For treatment of localized cutaneous infection, we suggest oral therapy with
         <a class="drug drug_general" data-topicid="9751" href="/z/d/drug information/9751.html" rel="external">
          penicillin V
         </a>
         or
         <a class="drug drug_general" data-topicid="8673" href="/z/d/drug information/8673.html" rel="external">
          amoxicillin
         </a>
         (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). In the setting of penicillin allergy,
         <a class="drug drug_general" data-topicid="9231" href="/z/d/drug information/9231.html" rel="external">
          cephalexin
         </a>
         (in the absence of immediate hypersensitivity to penicillin),
         <a class="drug drug_general" data-topicid="9267" href="/z/d/drug information/9267.html" rel="external">
          ciprofloxacin
         </a>
         or
         <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">
          clindamycin
         </a>
         are acceptable alternatives. Treatment duration is five to seven days; dosing is outlined in the table (
         <a class="graphic graphic_table graphicRef73058" href="/z/d/graphic/73058.html" rel="external">
          table 1
         </a>
         ). (See
         <a class="local">
          'Clinical approach'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For treatment of diffuse cutaneous disease, we suggest parenteral therapy with
         <a class="drug drug_general" data-topicid="9749" href="/z/d/drug information/9749.html" rel="external">
          penicillin G
         </a>
         (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Alternative therapies include
         <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">
          ceftriaxone
         </a>
         ,
         <a class="drug drug_general" data-topicid="8553" href="/z/d/drug information/8553.html" rel="external">
          imipenem
         </a>
         , a fluoroquinolone, or
         <a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">
          daptomycin
         </a>
         (
         <a class="graphic graphic_table graphicRef73058" href="/z/d/graphic/73058.html" rel="external">
          table 1
         </a>
         ). (See
         <a class="local">
          'Clinical approach'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For treatment of systemic infection with bacteremia (with or without endocarditis), we suggest parenteral therapy with
         <a class="drug drug_general" data-topicid="9749" href="/z/d/drug information/9749.html" rel="external">
          penicillin G
         </a>
         (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Alternative therapies include
         <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">
          ceftriaxone
         </a>
         ,
         <a class="drug drug_general" data-topicid="9214" href="/z/d/drug information/9214.html" rel="external">
          cefazolin
         </a>
         ,
         <a class="drug drug_general" data-topicid="8553" href="/z/d/drug information/8553.html" rel="external">
          imipenem
         </a>
         , a fluoroquinolone, or
         <a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">
          daptomycin
         </a>
         . Treatment duration is at least four weeks; dosing is outlined in the Table (
         <a class="graphic graphic_table graphicRef73058" href="/z/d/graphic/73058.html" rel="external">
          table 1
         </a>
         ). (See
         <a class="local">
          'Clinical approach'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Wang Q, Fidalgo S, Chang BJ, et al. The detection and recovery of Erysipelothrix spp. in meat and abattoir samples in Western Australia. J Appl Microbiol 2002; 92:844.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Veraldi S, Girgenti V, Dassoni F, Gianotti R. Erysipeloid: a review. Clin Exp Dermatol 2009; 34:859.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gorby GL, Peacock JE Jr. Erysipelothrix rhusiopathiae endocarditis: microbiologic, epidemiologic, and clinical features of an occupational disease. Rev Infect Dis 1988; 10:317.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang Q, Chang BJ, Riley TV. Erysipelothrix rhusiopathiae. Vet Microbiol 2010; 140:405.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McNamara DR, Zitterkopf NL, Baddour LM. A woman with a lesion on her finger and bacteremia. Clin Infect Dis 2005; 41:1005.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shimoji Y, Yokomizo Y, Sekizaki T, et al. Presence of a capsule in Erysipelothrix rhusiopathiae and its relationship to virulence for mice. Infect Immun 1994; 62:2806.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shimoji Y. Pathogenicity of Erysipelothrix rhusiopathiae: virulence factors and protective immunity. Microbes Infect 2000; 2:965.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhu W, Cai C, Wang Y, et al. Characterization of roles of SpaA in Erysipelothrix rhusiopathiae adhesion to porcine endothelial cells. Microb Pathog 2017; 113:176.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cheun HI, Kawamoto K, Hiramatsu M, et al. Protective immunity of SpaA-antigen producing Lactococcus lactis against Erysipelothrix rhusiopathiae infection. J Appl Microbiol 2004; 96:1347.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abrashev I, Orozova P. Erysipelothrix rhusiopathiae neuraminidase and its role in pathogenicity. Z Naturforsch C 2006; 61:434.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang Y, Li J, Zhang A, et al. iTRAQ-based quantitative proteomic analysis reveals potential virulence factors of Erysipelothrix rhusiopathiae. J Proteomics 2017; 160:28.
          </a>
         </li>
         <li class="breakAll">
          Hand WL, Ho H. Erysipelothrix. In: Current Therapy of Infectious Disease, 2nd ed, Schlossberg D (Ed), Mosby, Inc, St. Louis 2001. p.499.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Collier DN. Cutaneous infections from coastal and marine bacteria. Dermatol Ther 2002; 15:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Burke WA, Jones BE. Cutaneous infections of the coast. N C Med J 1987; 48:421.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Talan DA, Citron DM, Abrahamian FM, et al. Bacteriologic analysis of infected dog and cat bites. Emergency Medicine Animal Bite Infection Study Group. N Engl J Med 1999; 340:85.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           NELSON E. Five hundred cases of erysipeloid. Rocky Mt Med J 1955; 52:40.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ognibene FP, Cunnion RE, Gill V, et al. Erysipelothrix rhusiopathiae bacteremia presenting as septic shock. Am J Med 1985; 78:861.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schuster MG, Brennan PJ, Edelstein P. Persistent bacteremia with Erysipelothrix rhusiopathiae in a hospitalized patient. Clin Infect Dis 1993; 17:783.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Upapan P, Chayakulkeeree M. Erysipelothrix rhusiopathiae bacteremia without endocarditis associated with psoas abscess: the first case report in Thailand. J Med Assoc Thai 2014; 97 Suppl 3:S232.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Drekonja DM. Erysipelothrix bacteremia without endocarditis: rare event or under-reported occurrence? Diagn Microbiol Infect Dis 2013; 77:280.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jones N, Khoosal M. Erysipelothrix rhusiopathiae septicemia in a neonate. Clin Infect Dis 1997; 24:511.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tan EM, Marcelin JR, Adeel N, et al. Erysipelothrix rhusiopathiae bloodstream infection - A 22-year experience at Mayo Clinic, Minnesota. Zoonoses Public Health 2017; 64:e65.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Feasi M, Pontali E, Usiglio D, et al. Erysipelothrix rhusiopathiae septicaemia in systemic lupus erythematosus. Infez Med 2018; 26:356.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reboli AC, Farrar WE. Erysipelothrix rhusiopathiae: an occupational pathogen. Clin Microbiol Rev 1989; 2:354.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nielsen JJ, Blomberg B, Gaïni S, Lundemoen S. Aortic valve endocarditis with Erysipelothrix rhusiopathiae: A rare zoonosis. Infect Dis Rep 2018; 10:7770.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jean S, Lainhart W, Yarbrough ML. Closing the Brief Case: Erysipelothrix Bacteremia and Endocarditis in a 59-Year-Old Immunocompromised Male on Chronic High-Dose Steroids. J Clin Microbiol 2019; 57.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Altibi AM, Khalid M, Kak V, Patel B. Native valve endocarditis caused by ErysipelothrixRhusiopathiae: presenting with refractory heart failure and requiring surgical valve replacement-report on a rare zoonosis. BMJ Case Rep 2019; 12.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang T, Khan D, Mobarakai N. Erysipelothrix rhusiopathiae endocarditis. IDCases 2020; 22:e00958.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Skorupski WJ, Olasińska-Wiśniewska A, Kępski S, et al. Erysipelothrix rhusiopathiae Endocarditis in a Patient With Severe Unicuspid Aortic Valve Damage Complicated With Acquired Ventricular Septal Defect. Can J Cardiol 2021; 37:523.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rostamian M, Rahmati D, Akya A. Clinical manifestations, associated diseases, diagnosis, and treatment of human infections caused by Erysipelothrix rhusiopathiae: a systematic review. Germs 2022; 12:16.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fernández-Crespo P, Serra A, Bonet J, Gimenez M. Acute oliguric renal failure in a patient with an Erysipelothrix rhusiopathiae bacteremia and endocarditis. Nephron 1996; 74:231.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ruiz ME, Richards JS, Kerr GS, Kan VL. Erysipelothrix rhusiopathiae septic arthritis. Arthritis Rheum 2003; 48:1156.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Simionescu R, Grover S, Shekar R, West BC. Necrotizing fasciitis caused by Erysipelothrix rhusiopathiae. South Med J 2003; 96:937.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hardman SC, Carr SJ, Swann RA. Peritoneal dialysis-related peritonitis with bacteraemia due to Erysipelothrix rhusiopathiae. Nephrol Dial Transplant 2004; 19:1340.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hocqueloux L, Poisson DM, Sunder S, et al. Septic arthritis caused by Erysipelothrix rhusiopathiae in a prosthetic knee joint. J Clin Microbiol 2010; 48:333.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Feasi M, Bacigalupo L, Cappato S, et al. Erysipelothrix rhusiopathiae intra-abdominal abscess. Int J Infect Dis 2010; 14:e81.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Romney M, Cheung S, Montessori V. Erysipelothrix rhusiopathiae endocarditis and presumed osteomyelitis. Can J Infect Dis 2001; 12:254.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim SR, Kwon MJ, Lee JH, Lee NY. Chronic meningitis caused by Erysipelothrix rhusiopathiae. J Med Microbiol 2007; 56:1405.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Traer EA, Williams MR, Keenan JN. Erysipelothrix rhusiopathiae infection of a total knee arthroplasty an occupational hazard. J Arthroplasty 2008; 23:609.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Elvy J, Hanspal I, Simcock P. A case of Erysipelothrix rhusiopathiae causing bilateral endogenous endophthalmitis. J Clin Pathol 2008; 61:1223.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meric M, Ozcan SK. Erysipelothrix rhusiopathiae pneumonia in an immunocompetent patient. J Med Microbiol 2012; 61:450.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Andrychowski J, Jasielski P, Netczuk T, Czernicki Z. Empyema in spinal canal in thoracic region, abscesses in paravertebral space, spondylitis: in clinical course of zoonosis Erysipelothrix rhusiopathiae. Eur Spine J 2012; 21 Suppl 4:S557.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hofseth K, Dalen H, Kibsgaard L, et al. Infectious tenosynovitis with bloodstream infection caused by Erysipelothrix rhusiopathiae, a case report on an occupational pathogen. BMC Infect Dis 2017; 17:12.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gazeau P, Rezig S, Quaesaet L, et al. Erysipelothrix rhusiopathiae knee prosthesis infection. Med Mal Infect 2018; 48:372.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Groeschel M, Forde T, Turvey S, et al. An unusual case of Erysipelothrix rhusiopathiae prosthetic joint infection from the Canadian Arctic: whole genome sequencing unable to identify a zoonotic source. BMC Infect Dis 2019; 19:282.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maillard A, Wakim Y, Itani O, et al. Osteoarticular Infections Caused by Erysipelothrix rhusiopathiae: Case Report and Literature Review. Open Forum Infect Dis 2021; 8:ofab461.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mahon J, Phoenix E, Sundanum S, et al. Erysipelothrix rhusiopathiae Prosthetic Joint Infection in an Immunocompromised Patient: A Case Report. JBJS Case Connect 2021; 11.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dunbar SA, Clarridge JE 3rd. Potential errors in recognition of Erysipelothrix rhusiopathiae. J Clin Microbiol 2000; 38:1302.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Balkhair A, Al Lawati H, Al Riyami M, et al. Erysipelothrix rhusiopathiae endocarditis diagnosed by broad range 16s rRNA PCR gene sequencing. IDCases 2019; 18:e00584.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Farfour E, Leto J, Barritault M, et al. Evaluation of the Andromas matrix-assisted laser desorption ionization-time of flight mass spectrometry system for identification of aerobically growing Gram-positive bacilli. J Clin Microbiol 2012; 50:2702.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Klauder JV. Erysipeloid as an occupational disease. JAMA 1938; 111:1345.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Venditti M, Gelfusa V, Tarasi A, et al. Antimicrobial susceptibilities of Erysipelothrix rhusiopathiae. Antimicrob Agents Chemother 1990; 34:2038.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Soriano F, Fernández-Roblas R, Calvo R, García-Calvo G. In vitro susceptibilities of aerobic and facultative non-spore-forming gram-positive bacilli to HMR 3647 (RU 66647) and 14 other antimicrobials. Antimicrob Agents Chemother 1998; 42:1028.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America. Clin Infect Dis 2014; 59:147.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Piper KE, Steckelberg JM, Patel R. In vitro activity of daptomycin against clinical isolates of Gram-positive bacteria. J Infect Chemother 2005; 11:207.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jorgensen JH, Hindler JF. New consensus guidelines from the Clinical and Laboratory Standards Institute for antimicrobial susceptibility testing of infrequently isolated or fastidious bacteria. Clin Infect Dis 2007; 44:280.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rihana N, Hemminger A, Green S. Novel case of penicillin resistant E. rhusiopathiae septicemia: Case report with review of the literature. IDCases 2018; 11:67.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ding Y, Zhu D, Zhang J, et al. Virulence determinants, antimicrobial susceptibility, and molecular profiles of Erysipelothrix rhusiopathiae strains isolated from China. Emerg Microbes Infect 2015; 4:e69.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 5537 Version 27.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11972687" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : The detection and recovery of Erysipelothrix spp. in meat and abattoir samples in Western Australia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19663854" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Erysipeloid: a review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3287562" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Erysipelothrix rhusiopathiae endocarditis: microbiologic, epidemiologic, and clinical features of an occupational disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19733019" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Erysipelothrix rhusiopathiae.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16145779" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : A woman with a lesion on her finger and bacteremia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8005671" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Presence of a capsule in Erysipelothrix rhusiopathiae and its relationship to virulence for mice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10962280" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Pathogenicity of Erysipelothrix rhusiopathiae: virulence factors and protective immunity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29038054" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Characterization of roles of SpaA in Erysipelothrix rhusiopathiae adhesion to porcine endothelial cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15139928" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Protective immunity of SpaA-antigen producing Lactococcus lactis against Erysipelothrix rhusiopathiae infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16869504" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Erysipelothrix rhusiopathiae neuraminidase and its role in pathogenicity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28284755" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : iTRAQ-based quantitative proteomic analysis reveals potential virulence factors of Erysipelothrix rhusiopathiae.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28284755" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : iTRAQ-based quantitative proteomic analysis reveals potential virulence factors of Erysipelothrix rhusiopathiae.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Cutaneous infections from coastal and marine bacteria
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3480441" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Cutaneous infections of the coast.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9887159" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Bacteriologic analysis of infected dog and cat bites. Emergency Medicine Animal Bite Infection Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/13225543" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Five hundred cases of erysipeloid.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3993665" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Erysipelothrix rhusiopathiae bacteremia presenting as septic shock.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8268364" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Persistent bacteremia with Erysipelothrix rhusiopathiae in a hospitalized patient.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24772603" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Erysipelothrix rhusiopathiae bacteremia without endocarditis associated with psoas abscess: the first case report in Thailand.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23988830" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Erysipelothrix bacteremia without endocarditis: rare event or under-reported occurrence?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9114208" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Erysipelothrix rhusiopathiae septicemia in a neonate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28206705" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Erysipelothrix rhusiopathiae bloodstream infection - A 22-year experience at Mayo Clinic, Minnesota.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30555140" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Erysipelothrix rhusiopathiae septicaemia in systemic lupus erythematosus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2680056" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Erysipelothrix rhusiopathiae: an occupational pathogen.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30542523" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Aortic valve endocarditis with Erysipelothrix rhusiopathiae: A rare zoonosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31127014" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Closing the Brief Case: Erysipelothrix Bacteremia and Endocarditis in a 59-Year-Old Immunocompromised Male on Chronic High-Dose Steroids.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31862813" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Native valve endocarditis caused by ErysipelothrixRhusiopathiae: presenting with refractory heart failure and requiring surgical valve replacement-report on a rare zoonosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32995274" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Erysipelothrix rhusiopathiae endocarditis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32920167" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Erysipelothrix rhusiopathiae Endocarditis in a Patient With Severe Unicuspid Aortic Valve Damage Complicated With Acquired Ventricular Septal Defect.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35601944" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Clinical manifestations, associated diseases, diagnosis, and treatment of human infections caused by Erysipelothrix rhusiopathiae: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8883054" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Acute oliguric renal failure in a patient with an Erysipelothrix rhusiopathiae bacteremia and endocarditis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12687560" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Erysipelothrix rhusiopathiae septic arthritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14513997" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Necrotizing fasciitis caused by Erysipelothrix rhusiopathiae.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15102991" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Peritoneal dialysis-related peritonitis with bacteraemia due to Erysipelothrix rhusiopathiae.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19923477" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Septic arthritis caused by Erysipelothrix rhusiopathiae in a prosthetic knee joint.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19481488" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Erysipelothrix rhusiopathiae intra-abdominal abscess.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18159347" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Erysipelothrix rhusiopathiae endocarditis and presumed osteomyelitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17893181" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Chronic meningitis caused by Erysipelothrix rhusiopathiae.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18514883" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Erysipelothrix rhusiopathiae infection of a total knee arthroplasty an occupational hazard.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18818268" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : A case of Erysipelothrix rhusiopathiae causing bilateral endogenous endophthalmitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22096132" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Erysipelothrix rhusiopathiae pneumonia in an immunocompetent patient.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22526696" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Empyema in spinal canal in thoracic region, abscesses in paravertebral space, spondylitis: in clinical course of zoonosis Erysipelothrix rhusiopathiae.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28056818" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Infectious tenosynovitis with bloodstream infection caused by Erysipelothrix rhusiopathiae, a case report on an occupational pathogen.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29656843" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Erysipelothrix rhusiopathiae knee prosthesis infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30909869" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : An unusual case of Erysipelothrix rhusiopathiae prosthetic joint infection from the Canadian Arctic: whole genome sequencing unable to identify a zoonotic source.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34708142" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Osteoarticular Infections Caused by Erysipelothrix rhusiopathiae: Case Report and Literature Review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34910716" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Erysipelothrix rhusiopathiae Prosthetic Joint Infection in an Immunocompromised Patient: A Case Report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10699048" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Potential errors in recognition of Erysipelothrix rhusiopathiae.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31338300" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Erysipelothrix rhusiopathiae endocarditis diagnosed by broad range 16s rRNA PCR gene sequencing.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22692743" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Evaluation of the Andromas matrix-assisted laser desorption ionization-time of flight mass spectrometry system for identification of aerobically growing Gram-positive bacilli.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Erysipeloid as an occupational disease
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2291674" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Antimicrobial susceptibilities of Erysipelothrix rhusiopathiae.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9593121" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : In vitro susceptibilities of aerobic and facultative non-spore-forming gram-positive bacilli to HMR 3647 (RU 66647) and 14 other antimicrobials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24947530" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16133715" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : In vitro activity of daptomycin against clinical isolates of Gram-positive bacteria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17173232" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : New consensus guidelines from the Clinical and Laboratory Standards Institute for antimicrobial susceptibility testing of infrequently isolated or fastidious bacteria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29619324" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Novel case of penicillin resistant E. rhusiopathiae septicemia: Case report with review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26975059" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Virulence determinants, antimicrobial susceptibility, and molecular profiles of Erysipelothrix rhusiopathiae strains isolated from China.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
